---
url: https://www.servicesaustralia.gov.au/non-small-cell-lung-cancer
title: Non-small cell lung cancer - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:29.183Z
source: servicesaustralia.gov.au
---
# Non-small cell lung cancer

The PBS subsidises crizotinib and entrectinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).

## on this page

-   [Patient eligibility](#a1)
-   [Treatment specifics](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

Please note: Youâ€™ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with crizotinib and entrectinib under the _National Health Act 1953_, section 85 for patients with Stage IIIB or Stage IV NSCLC.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing crizotinib and entrectinib.

## Treatment specifics

### Crizotinib

To be eligible for initial PBS-subsidised treatment with crizotinib, patients must be treated by a medical practitioner.

To be eligible for continuing PBS-subsidised treatment with crizotinib, patients must be treated by either a:

-   medical practitioner
-   nurse practitioner where patient care is being shared with a medical practitioner and the prescription continues existing therapy with this medicine.

### Entrectinib

To be eligible for PBS-subsidised treatment with entrectinib, patients must be treated by a medical practitioner.

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised crizotinib or entrectinib to treat Stage IIIB or Stage IV NSCLC can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [non-small cell lung cancer - crizotinib or entrectinib - initial authority application form](/pb156?context=20)
-   relevant attachments.

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised crizotinib or entrectinib to treat Stage IIIB or Stage IV NSCLC can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
